Received: 16 October 2018
Accepted: 9 January 2019
First Online: 6 February 2019
Ethics approval and consent to participate
: This retrospective, single-center study was approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center.
: This study was granted waiver for consent.
: Dr. Amir A Jazaeri received research funding from Iovance, AstraZeneca, Bristol-Myers Squibb, Pfizer, Lilly, served on Advisory Board for Iovance, Aravive, Almac, and Data Safety Monitoring Board for Genetech. Dr. Ramona Dadu received research funding from Merck, Eisai, AstraZeneca, and served on Advisory Board for Bristol-Myers Squibb. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.